Vancenase AQ advisory committee review postponed at Schering-Plough's request.
This article was originally published in The Tan Sheet
SCHERING-PLOUGH VANCENASE AQ ADVISORY COMMITTEE REVIEW POSTPONED at the company's request. Review of Schering's Rx-to-OTC switch application for Vancenase AQ (beclomethasone dipropionate) nasal spray by FDA's Nonprescription Drugs and Pulmonary-Allergy Advisory Committees had been scheduled for Oct. 11. The company is seeking approval of the drug as an OTC treatment for seasonal allergic rhinitis ("The Tan Sheet" Sept. 9, p. 1).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC